Early Assessment of COVID-19 epidemiology and Vaccine/anti-viral Effectiveness (EAVE II)
- Funded by Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR), UK Research and Innovation (UKRI)
- Total publications:69 publications
Grant number: MC_PC_19075
Grant search
Key facts
Disease
COVID-19Start & end year
20202022Known Financial Commitments (USD)
$698,668.73Funder
Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR), UK Research and Innovation (UKRI)Principal Investigator
PendingResearch Location
United KingdomLead Research Institution
University of EdinburghResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Pathogen genomics, mutations and adaptations
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
This COVID-19 Rapid Response award is jointly funded (50:50) between the Medical Research Council and the National Institute for Health Research. The figure displayed is the total award amount of the two funders combined, with each partner contributing equally towards the project. EAVE (Early Estimation of vaccine and Anti-Viral Effectiveness) was a NIHR-funded project on pandemic influenza, which created a Scotland-wide cohort of 227,000 individuals recruited from 40 general practices together with stored serology samples from 1,000 individuals. EAVE established a national electronic cohort though linking health data sets from general practice, prescribing, hospitalisations and virology testing using the unique Community Health Identification (CHI) number for residents of Scotland. We plan to repurpose and expand this cohort to collect electronic data from 1.2m individuals living in Scotland to study COVID-19. We will augment the cohort by collecting and storing residual sera samples and by sequencing virus from patient specimens. Both of these, are being taken as part of routine care from a sample of these individuals. We will track the progress of the COVID-19 epidemic in near real-time using the EAVE II cohort. We will be able to model the full course of the epidemic from genome sequence data. Once a serological test becomes available we will be able to refine this model and provide precise estimates of the attack rates in different sub-populations, and accompanying hospitalisation and fatality rates. EAVE II will help to identify the clinical features of the epidemic and, in due course, provide estimates of the effectiveness of any vaccines and anti-viral therapies deployed. Ethical and Privacy Committee approval has previously been given for the EAVE study and we anticipate the same approvals will readily be obtained for this follow-on study.
Publicationslinked via Europe PMC
Last Updated:a day ago
View all publications at Europe PMC